Infant formula milk powder capable of improving intestinal inflammation and recovering key flora as well as preparation method and application of infant formula milk powder

Abstract

The invention provides infant formula milk powder for improving intestinal inflammation and recovering key flora as well as a preparation method and application of the infant formula milk powder. The invention firstly provides the infant formula milk powder, the infant formula milk powder comprises 2 '-fucosyllactose and osteopontin, the mass ratio of the 2'-fucosyllactose to the osteopontin is 1: (0.017-1.3), and every 100 g of the infant formula milk powder comprises 8-24 g of protein, 14-31 g of fat, 0.83-7.6 g of dietary fiber and 50-61 g of carbohydrate. The infant formula milk powder can improve intestinal inflammation and recover key flora.

Description

Technical Field

[0001] The present invention belongs to the technical field of infant formula milk powder, and specifically relates to an infant formula milk powder containing 2'-fucosyllactose and osteopontin, which helps to improve intestinal inflammation and restore key flora, and its preparation method and application. Background Art

[0002] As the most ideal nutritional source for infants, the unique composition of breast milk plays a crucial role in the growth, development and health maintenance of infants. In recent years, human milk oligosaccharides (HMO) and osteopontin (OPN), as two key active components in breast milk, have received extensive and in-depth attention in the field of food science.

[0003] Human milk oligosaccharides are the third largest solid component in breast milk after lactose and fat. They are composed of 3-10 monosaccharide units linked by glycosidic bonds and have a high degree of structural diversity, with more than 200 identified structures. It cannot be decomposed by human gastrointestinal digestive enzymes, but can play a unique prebiotic role in the intestine, providing exclusive "food" for beneficial intestinal bacteria, promoting the growth and colonization of beneficial flora such as Bifidobacterium, inhibiting the reproduction of harmful bacteria, thus effectively regulating the intestinal microecological balance and preventing intestinal problems such as diarrhea and constipation. At the same time, human milk oligosaccharides can also act as immune regulators, indirectly affecting the non-specific immune response of infants by interacting with receptors on the surface of intestinal epithelial cells, stimulating the body to generate immune active substances, enhancing the vitality of immune cells, improving the immunity of infants, and reducing the risk of infection and allergy.

[0004] Osteopontin is a highly glycosylated and phosphorylated acidic protein that is widely present in various tissues and body fluids of the human body, especially abundant in breast milk, and has the highest content in colostrum. In the early development stage of infants, osteopontin plays a crucial role. It can not only promote bone growth and increase bone density, laying a solid foundation for bone development, but also act as an important immune regulatory factor, participating in the activation, proliferation and migration of immune cells, regulating the intensity of immune response, inhibiting the excessive secretion of inflammatory factors, maintaining immune homeostasis, and helping infants resist the invasion of external pathogens. In addition, osteopontin also plays an active role in the intestine, promoting the proliferation and repair of intestinal cells, maintaining the integrity of the intestinal barrier, and enhancing the immune defense function of the intestine.

[0005] The first 1000 days of life is a window of opportunity for infant development. The dynamic development of the intestinal microecology complements the development of the intestinal immune system. The intestine is not only an important place for the digestion and absorption of nutrients, but also an important barrier to defend against external pathogens. Maintaining intestinal homeostasis and enhancing intestinal immune function are essential for maintaining body health. After birth, infants and young children are at high risk of gastrointestinal infections, inflammations and allergic diseases due to their immature digestive and immune functions and the unstable formation and development of intestinal flora. Breast milk is the first food that infants come into contact with. Breast milk is not only rich in nutrients, but also rich in immune active ingredients, growth factors and oligosaccharides. These ingredients in breast milk can not only provide immune support for infants and promote the maturation of intestinal barrier function, but also provide nutrients for probiotics such as bifidobacteria and lactobacilli, which helps to form a good microecological environment and ensure intestinal health. Literature results show that the infant's intestinal flora is closely related to the infant's development and the formation of the immune system. Establishing a healthy intestinal flora in the first 1000 days of life plays an important role / influence on the development and maturation of the intestinal mucosal immune system and the systemic immune system. The structure and relative abundance of the intestinal flora in early life will affect the probability of disease in the future.

[0006] In addition, there are a large number of keystone species in healthy humans, which play an important role in the species diversity and functional diversity of intestinal microorganisms and are indispensable. The specific composition of keystone microorganisms in infants and young children still needs to be further clarified. Some literature points out that the intestinal microbiome of infants is mainly composed of five phyla: Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria and Verrucomicrobia. A large number of studies have shown that the difference between the intestinal flora of diseased organisms and healthy organisms is mainly manifested in the decrease in the relative abundance of Firmicutes in the intestines of diseased organisms and the increase in the relative abundance of Proteobacteria.

[0007] Providing infants and young children with a nutritional composition that can prevent and / or improve intestinal inflammatory symptoms and restore key flora is essential for the healthy growth of infants and young children. Summary of the invention

[0008] One object of the present invention is to provide an infant formula milk powder which can improve intestinal inflammation and restore key flora.

[0009] Another object of the present invention is to provide a method for preparing the infant formula milk powder.

[0010] Another object of the present invention is to provide related applications of the infant formula milk powder.

[0011] On the one hand, the present invention provides an infant formula milk powder, which comprises 2'-fucosyllactose and osteopontin, and the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.017 - 1.3); every 100 g of the infant formula milk powder comprises 8 - 24 g of protein, 14 - 31 g of fat, 0.83 - 7.6 g of dietary fiber, and 50 - 61 g of carbohydrates.

[0012] 2'-fucosyllactose (2'-FL or 2-FL) is a trisaccharide structure formed by fucose and lactose, and is a representative substance of fucosylated oligosaccharides. The commercially available product of this substance is usually prepared by microbial fermentation method and has the same structure as the oligosaccharides found in human milk.

[0013] Osteopontin (OPN) is a secreted, phosphorylated integrin-binding protein and an atypical immunomodulatory factor, and its role in regulating immune responses has been clearly established. OPN can promote cell survival and inhibit apoptosis, which plays a key role in intestinal mucosal protection. According to specific embodiments of the present invention, in the infant formula milk powder of the present invention, the raw material providing osteopontin can be a commercially available food-grade raw material with a relatively high purity specifically for providing osteopontin, or a whey protein powder rich in osteopontin. In addition, raw cow milk, skim milk powder, and demineralized whey powder can also provide part of the osteopontin.

[0014] The present invention has found through research that combining 2'-fucosyllactose and osteopontin in a specific ratio has a synergistic effect on improving intestinal inflammation symptoms and restoring key intestinal flora.

[0015] According to some specific embodiments of the present invention, the infant formula milk powder of the present invention is an infant formula food for special medical purposes or a toddler formula food for special medical purposes.

[0016] According to some specific embodiments of the present invention, in the infant formula milk powder of the present invention, the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.1 - 1.3).

[0017] According to some specific embodiments of the present invention, in the infant formula milk powder of the present invention, the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.2 - 1.3).

[0018] According to some specific embodiments of the present invention, in the infant formula milk powder of the present invention, the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.25 - 1.3).

[0019] According to some specific embodiments of the present invention, in the infant formula of the present invention, the content of 2'-fucosyllactose is 0.5-1.8 g / 100 g. The amount of osteopontin can be determined with reference to the aforementioned ratio range of 2'-fucosyllactose to osteopontin.

[0020] According to some specific embodiments of the present invention, in the infant formula of the present invention, the content of 2'-fucosyllactose is 0.6-1.7 g / 100 g, and the content of osteopontin is 0.03-0.09 g / 100 g.

[0021] According to some specific embodiments of the present invention, in the infant formula of the present invention, the amount of 2'-fucosyllactose is 0.6-1.6 g / 100 g.

[0022] According to some specific embodiments of the present invention, in the infant formula of the present invention, the amount of 2'-fucosyllactose is 0.7-1.4 g / 100 g.

[0023] According to some specific embodiments of the present invention, in the infant formula of the present invention, the content of 2'-fucosyllactose is 0.7-1.2 g / 100 g, and the content of osteopontin is 0.03-0.08 g / 100 g.

[0024] According to some specific embodiments of the present invention, in the infant formula of the present invention, the amount of 2'-fucosyllactose is 0.8-1.3 g / 100 g.

[0025] According to some specific embodiments of the present invention, in the infant formula of the present invention, the amount of 2'-fucosyllactose is 0.6-0.7 g / 100 g, 0.8-0.9 g / 100 g, 1.0-1.1 g / 100 g, 1.2-1.3 g / 100 g, 1.4-1.5 g / 100 g or 1.6-1.7 g / 100 g. The amount of osteopontin can be determined with reference to the aforementioned ratio range of 2'-fucosyllactose to osteopontin.

[0026] According to a specific embodiment of the present invention, in the infant formula of the present invention, the sources of the protein include any one or more of raw cow milk, raw goat milk, whey protein powder, demineralized whey powder, demineralized whey liquid, α-lactalbumin powder, β-casein powder, and skimmed milk powder, wherein the mass content of whey protein in the protein is 20-90%. In a specific embodiment of the present invention, based on 1000 parts by weight of the infant formula, its raw materials include: 500-4000 parts by weight of raw cow milk, 0-450 parts by weight of skimmed milk powder, and part or all of the raw cow milk and skimmed milk powder can be replaced with whole milk powder or skimmed milk with equivalent protein content, and 7-20 parts of 2'-fucosyllactose. In a specific embodiment of the present invention, based on 1000 parts by weight of the infant formula, its raw materials include: 0-300 parts by weight of whey protein powder, 25-450 parts by weight of demineralized whey powder, and 7-20 parts of 2'-fucosyllactose.

[0027] According to a specific embodiment of the present invention, in the infant formula of the present invention, preferably, each 100 g of the infant formula contains 1800-5000 mg of linoleic acid and 200-500 mg of α-linolenic acid. In addition, the raw materials for providing fat may optionally include the raw material OPO structured lipid added for providing 1,3-dioleoyl-2-palmitoyl glycerol, wherein the content of the active ingredient 1,3-dioleoyl-2-palmitoyl glycerol is 40%-70%. The content of linoleic acid in the OPO structured lipid is 5.9-6.3%, and the content of α-linolenic acid is 0.4-0.62%. The effective content of 1,3-dioleoyl-2-palmitoyl glycerol in the raw materials of the OPO structured lipid is 40%-70%. In a specific embodiment of the present invention, based on 1000 parts by weight of the infant formula, its raw materials include: 0-80 parts by weight of sunflower oil; 0-50 parts by weight of corn oil; 0-80 parts by weight of soybean oil; 0-140 parts by weight of OPO structured lipid.

[0028] According to a specific embodiment of the present invention, in the infant formula of the present invention, the sources of the dietary fiber include one or more of fructooligosaccharide, galactooligosaccharide, raffinose, and human milk oligosaccharide.

[0029] According to specific embodiments of the present invention, in the infant formula of the present invention, a part of the carbohydrates comes from basic raw materials containing lactose such as milk, whole milk powder and / or skimmed milk powder, etc., and the remaining part comes from additionally added lactose raw materials. That is, in the infant formula of the present invention, the raw materials providing carbohydrates include, in addition to the basic raw materials containing lactose, raw material lactose. In a specific embodiment of the present invention, based on 1000 parts by weight of the infant formula of the present invention, its raw materials include: 100 - 550 parts by weight of lactose. The specific addition amount of lactose can be adjusted within the above range so that the carbohydrate content of the infant formula of the present invention is 50 - 59 g / 100 g.

[0030] According to specific embodiments of the present invention, the raw materials of the infant formula of the present invention may also include one or more combinations of appropriate DHA, ARA, nucleotides, lactoferrin, etc. Preferably, based on 1000 parts by weight of the infant formula of the present invention, its raw materials include: 0 - 15 parts by weight of DHA, 0 - 25 parts by weight of ARA, 0 - 1.5 parts by weight of lactoferrin, and 0 - 0.8 parts by weight of nucleotides.

[0031] According to specific embodiments of the present invention, the raw materials of the infant formula of the present invention may also include a compound nutrient containing calcium powder, vitamins and minerals. This compound nutrient is a combination of nutritional components that meet national standards, and different addition amounts are used according to different formulas. Preferably, based on 1000 parts by weight of the infant formula, its raw materials include: 7 - 22 parts by weight of a compound nutrient containing calcium powder, vitamins and minerals. More preferably, the compound nutrient is added at least in the form of a compound vitamin package, calcium powder, and mineral nutrient package. Specifically, the compound nutrient is preferably added in the form of the following nutrient packages:

[0032] 1) Compound vitamin nutrient package, the content of each component in each gram of the compound vitamin nutrient package is as follows:

[0033] Taurine: 130 - 220 mg

[0034] Vitamin A: 1400 - 2700 μg RE

[0035] Vitamin D: 30 - 68 μg

[0036] Vitamin B1: 1400 - 3200 μg

[0037] Vitamin B2: 880 - 3600 μg

[0038] Vitamin B6: 1040 - 2800 μg

[0039] Vitamin B12: 4 - 9.7 μg

[0040] Vitamin K1: 150 - 300 μg

[0041] Vitamin C: 145 - 500 mg

[0042] Vitamin E: 12 - 50 mg α-TE

[0043] Nicotinamide: 10000 - 23000 μg

[0044] Folic acid: 210 - 420 μg

[0045] Biotin: 30 - 85 μg

[0046] Pantothenic acid: 7100 - 13800 μg

[0047] Inositol: 0 - 250 mg

[0048] L-carnitine: 0 - 60 mg;

[0049] 2) Mineral Nutrition Pack 1. The content of each component per gram of Mineral Nutrition Pack 1 is as follows:

[0050] Iron: 45 - 95 mg

[0051] Zinc: 22 - 78 mg

[0052] Copper: 2600 - 4420 μg

[0053] Iodine: 500 - 1550 μg

[0054] Selenium: 0 - 260 μg

[0055] Manganese: 0 - 810 μg;

[0056] 3) Mineral Nutrition Pack 2. The content of each component per gram of Mineral Nutrition Pack 2 is as follows:

[0057] Calcium: 150 - 345 mg

[0058] Phosphorus: 35 - 76 mg

[0059] Sodium: 30 - 96 mg;

[0060] 4) Magnesium Chloride Nutrition Pack. The effective magnesium content is 10% - 16%;

[0061] 5) Potassium Chloride Nutrition Pack. The effective potassium content is 49% - 53%;

[0062] 6) Choline Chloride Nutrition Pack. The effective choline content is 72% - 76%.

[0063] Preferably, based on 1000 parts by weight of the infant formula milk powder, the addition amount of the compound vitamin nutrition package is 2-4 parts by weight, the addition amount of the mineral two nutrition package is 2-12 parts by weight, the addition amount of the mineral one nutrition package is 0.5-3 parts by weight, the addition amount of the magnesium chloride nutrition package is 0-2 parts by weight, the addition amount of the potassium chloride nutrition package is 0-4.5 parts by weight, the addition amount of the choline chloride nutrition is 0-2 parts by weight, and the base material of each nutrition package is preferably lactose or sodium L-ascorbate.

[0064] The content of each component of the above compound nutrients refers to the addition amount for strengthening the nutrient substances, and does not include the nutrient component content in other raw materials of the milk powder. For example, the calcium powder (calcium carbonate) in the mineral two, "calcium: 1300-1600 g" per 1000 kg of milk powder means that for strengthening the calcium element in the product, based on 1000 kg of milk powder, the mineral two (such as calcium carbonate) nutrition package is added with 1300-1600 g in terms of the weight of the calcium element therein.

[0065] According to the specific implementation scheme of the present invention, the raw materials of the infant formula milk powder of the present invention may further include probiotics. Preferably, the probiotics are Bifidobacterium. More preferably, based on 1000 parts by weight of the infant formula milk powder, the addition amount of Bifidobacterium is 0.1-0.4 parts by weight; more preferably 0.15-0.2 parts by weight. More preferably, each part by weight of the Bifidobacterium powder contains Bifidobacterium 10 CFU or more.

[0066] According to the specific implementation scheme of the present invention, the raw materials of the infant formula milk powder of the present invention preferably include:

[0067]

[0068]

[0069] It can be understood that in the infant formula milk powder of the present invention, the specific dosage of each raw material should be adjusted and determined on the premise of meeting the product index requirements of the infant formula milk powder. For the infant formula milk powder of the present invention, the product performance indexes not detailed or listed should be implemented in accordance with the national standards and relevant standards and regulations of the infant formula milk powder or the modified milk powder.

[0070] In the infant formula milk powder of the present invention, each raw material can be commercially obtained, and the selection of each raw material should meet the relevant standard requirements, and the protein composition should meet the requirements described in the present invention. In addition, the compound nutrients can also be compounded by oneself. In the present invention, "compound" is only used for convenient expression, and does not mean that the components in the compound must be mixed together first and then applied. Each raw material should be added and used on the premise of meeting the relevant regulations.

[0071] On the other hand, the present invention also provides a method for preparing the infant formula milk powder, which method comprises:

[0072] Adopting a wet method, a dry method or a combined wet and dry production process, mixing the raw materials providing 2'-fucosyllactose and osteopontin with other raw materials in the formula, and subjecting the mixed material to homogenization treatment after filtering to remove impurities, and further using the same for preparing the infant formula milk powder.

[0073] According to some specific embodiments of the present invention, the method for preparing the infant formula milk powder of the present invention comprises:

[0074] Mixing the roughly filtered, homogenized and sterilized milk, powder raw materials and melted oil raw materials, adding galactooligosaccharide syrup into a small hopper, and adding compound nutrients into a nutrient cylinder to obtain a mixed material liquid;

[0075] Filtering, homogenizing, cooling, concentrating and sterilizing, spray drying and fluidized bed drying and cooling the mixed material liquid to obtain dry milk powder, mixing the dry milk powder with selectively added DHA, ARA, lactoferrin, nucleotides and bifidobacterium, and screening to obtain the infant milk powder.

[0076] Preferably, in the method for preparing the infant formula milk powder of the present invention, the primary pressure of the homogenization treatment of the mixed material liquid is 105±5 bar, and the secondary pressure is 32±3 bar;

[0077] Preferably, in the method for preparing the infant formula milk powder of the present invention, double-effect concentration is adopted for concentration and sterilization; more preferably, the sterilization temperature is ≥83°C and the sterilization time is 25 seconds; further preferably, the discharge concentration is 48%-52% dry matter;

[0078] Preferably, in the method for preparing the infant formula milk powder of the present invention, the inlet air temperature of the spray drying is 165-180°C, the exhaust air temperature is 75-90°C, the high-pressure pump pressure is 160-210 bar, and the tower negative pressure is -4 mbar to -2 mbar;

[0079] Preferably, in the method for preparing the infant formula milk powder of the present invention, the fluidized bed drying and cooling comprises two times of drying and cooling, and the temperature of the milk powder after the secondary drying and cooling is 25-30°C; meanwhile, phospholipids and a carrier are mixed and heated to 60-65°C, and are uniformly dispersed on the surface of the milk powder under the action of compressed air.

[0080] In a specific embodiment of the present invention, the preparation process of the infant formula milk powder of the present invention may comprise the following specific steps:

[0081] 1) Coarse filtration of milk: After the milk is roughly filtered and degassed in a balance cylinder, it is preheated through a plate heat exchanger and then separated from impurities through a separator.

[0082] 2) Homogenization and sterilization of milk: After removing impurities, part of the milk enters the homogenizer for homogenization, and the other part is not homogenized. The homogenized milk and the non-homogenized milk are mixed and then enter the sterilization system for sterilization. After sterilization, it enters the mixing tank.

[0083] 3) Addition of powder materials: The raw materials are premixed in the optimal proportion, and the temperature of the ingredients is maintained at 35 - 55°C. High-shear technology is adopted, and the shear speed is higher than 1590 r / min. Other various powder raw materials are metered according to the formula and uniformly added to the powder mixing tank for storage through the pneumatic conveying system.

[0084] 4) Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the mixing tank through the vacuum system.

[0085] 5) Melting and oil blending: Put the specified grease in the formula into the oil melting room according to the formula requirements. The temperature in the oil melting room should be maintained at 50 - 90°C. After the oil is melted, it is pumped into the mixed oil storage tank through the oil pump and flowmeter according to the formula ratio requirements.

[0086] 6) Storage of mixed oil: The mixed oil is stored in the oil storage tank with heat preservation, the temperature is 40 - 50°C, and the storage time is less than 12 hours to prevent fat oxidation.

[0087] 7) Weighing: Pump the mixed oil into the mixing tank according to the formula requirements through the oil pump.

[0088] 8) Dissolution and addition of compound nutritional fortifiers: Compound nutritional fortifier one, compound nutritional fortifier two, compound nutritional fortifier three, compound magnesium chloride nutritional package, compound potassium chloride nutritional package and choline chloride are added respectively. After being dissolved with 100 - 200 kg of pure water respectively, they are pumped into the mixing tank. After each addition, the addition tank and pipeline are rinsed with 100 kg of pure water.

[0089] 9) Addition of minor ingredients: Add galacto-oligosaccharide syrup in the minor ingredient hopper and pump it into the mixing tank.

[0090] 10) Filtration: Mix the raw materials in each part in the mixing tank. The obtained liquid is filtered through a filter screen to remove possible physical impurities in the raw materials.

[0091] 11) Homogenization: The mixed liquid is homogenized through the homogenizer. The primary pressure is 105 ± 5 bar, and the secondary pressure is 32 ± 3 bar. The fat globules are mechanically processed and dispersed into uniform fat globules.

[0092] 12) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling, cooled to below 20°C, and temporarily stored in the pre-storage tank. It enters the next process within 6 hours, and the stirrer is started according to the set requirements.

[0093] 13) Concentration and sterilization: Double-effect concentration is used during production. The sterilization temperature is ≥83°C, and the sterilization time is 25 seconds. The outlet concentration is 48%-52% dry matter.

[0094] 14) Storage, preheating, filtration, and spray drying of concentrated milk: The concentrated milk is temporarily stored in a concentrated milk balance tank; it is preheated to 60-70°C by a scraper preheater. After preheating, the material is filtered through a filter with a 1-mm pore size and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Among them, the inlet air temperature is 165-180°C, the exhaust air temperature is 75-90°C, the pressure of the high-pressure pump is 160-210 bar, and the tower negative pressure is -4 mbar to -2 mbar.

[0095] 15) Fluidized bed drying and cooling: The milk powder coming out of the drying tower is further dried in the fluidized bed (first stage) and then cooled to 25-30°C in the fluidized bed (second stage); at the same time, phospholipids and carriers are mixed and heated to 60-65°C. Under the action of compressed air, the phospholipids are evenly dispersed on the surface of the milk powder to increase the particle size and instant solubility of the powder particles through agglomeration.

[0096] 16) Sub-packaging: According to the formula requirements, DHA, ARA, lactoferrin, nucleotides, and bifidobacteria are weighed, bagged, and sub-packaged.

[0097] 17) Dry mixing: The weighed DHA, ARA, lactoferrin, nucleotides, and bifidobacteria are evenly mixed with the milk powder in a dry mixer.

[0098] 18) Sieving the powder: Through a vibrating sieve, the particle size of the milk powder is made uniform, and the powder residue is scrapped.

[0099] 19) Powder discharging: The powder is collected with a disinfected powder collecting box and transported from the powder discharging room to the powder feeding room.

[0100] 20) Powder feeding: The milk powder is poured into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0101] 21) Packaging: Nitrogen is filled for packaging with automatic packaging machines of different specifications; when filling nitrogen, the oxygen content is less than 1-5%.

[0102] 22) Boxing: The packaged small bags are put into cartons, and a powder spoon is added at the same time, and then sealed with a carton sealer.

[0103] 23) Final product inspection: The packaged products are sampled and inspected according to the inspection plan.

[0104] 24) Storage in warehouse: The products that pass the inspection are stored in the warehouse. It is required to be stored at normal temperature with a humidity ≤65%.

[0105] In the preparation method of the present invention, ① according to the addition of 2'-fucosyllactose and osteopontin, the formula is optimized, which can improve intestinal inflammation and restore key flora, ensuring that infants, young children and children can fully absorb and utilize these key nutrients. ② Mixing and formulation: Each component is uniformly mixed according to a specific ratio to ensure that the nutrient components in each formula food are consistent and avoid nutritional imbalance. Uniform mixing helps 2'-fucosyllactose and osteopontin play their best roles in the intestine, ensuring the consistent effect of the product. ③ Production and processing: Advanced production processes such as homogenization and sterilization are adopted to ensure the safety and quality of the product, extend the shelf life, and at the same time retain the activity and stability of the nutrient components.

[0106] On the other hand, the present invention also provides the use of the infant formula milk powder described above in the preparation of a product for improving intestinal inflammation symptoms and restoring key flora. The product described above can be the infant formula milk powder of any of the foregoing embodiments of the present invention, or can be other products further prepared based on the infant formula milk powder of the present invention.

[0107] According to the specific implementation embodiments of the present invention, the improvement of intestinal inflammation symptoms and the restoration of key flora include one or more of the following:

[0108] Improving weight loss caused by intestinal inflammatory response;

[0109] Improving intestinal damage caused by inflammatory response;

[0110] Reducing the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammatory response;

[0111] Reducing the increase in serum diamine oxidase (DAO) level caused by intestinal inflammatory response;

[0112] Enhancing the level of intestinal goblet cells (improving the decrease in the level of circular cells caused by intestinal inflammatory response);

[0113] Improving intestinal barrier function;

[0114] Enhancing intestinal physical and / or mucus barrier;

[0115] Increasing the expression level of intestinal mucin (improving the decrease in mucin level caused by intestinal inflammatory response);

[0116] Increasing the expression level of intestinal tight junction proteins (improving the decrease in tight junction protein level caused by intestinal inflammatory response);

[0117] Maintaining intestinal cell immune homeostasis;

[0118] Improving intestinal immune cell dysregulation caused by inflammatory response;

[0119] Enhance the expression of intestinal CD4+ T cells;

[0120] Reduce the expression of intestinal CD8+ T cells;

[0121] Increase the ratio of intestinal CD4+ / CD8+ T cells;

[0122] Enhance the diversity and / or community richness of the intestinal microbiota;

[0123] Restore the disorder or reduced diversity of the intestinal keystone microbiota caused by inflammation or antibiotics;

[0124] Improve the reduction of intestinal microbial species caused by intestinal mucosal immune damage;

[0125] Increase the abundance of the intestinal genera Muribaculaceae and / or Lactobacillus;

[0126] Reduce the abundance of the intestinal genera Escherichia-Shigella and / or Alloprevotella.

[0127] Overall, the present invention mixes and compound 2'-fucosyllactose and osteopontin in a certain proportion for preparing infant formula milk powder, which helps to improve intestinal inflammation and restore key microbiota, and is beneficial to the healthy growth of infants and children. Brief Description of the Drawings

[0128] Figure 1 Show the weight changes of rats in each group after LPS treatment for 6 h in a specific experiment of the present invention.

[0129] Figure 2 Show the weight loss of rats in each group after LPS treatment for 6 h in a specific experiment of the present invention.

[0130] Figure 3 Show the MPO activity in the serum of rats in each group in a specific experiment of the present invention.

[0131] Figure 4 Show the DAO level in the serum of rats in each group in a specific experiment of the present invention.

[0132] Figure 5 Show the effect on the number of goblet cells in the intestine of rats in each group in a specific experiment of the present invention.

[0133] Figure 6A - Figure 6D Respectively show the expression of mucin and tight junction proteins in the colon tissues of rats in each group in a specific experiment of the present invention.

[0134] Figure 7A - Figure 7C Respectively show the expression of immune cells in each group in a specific experiment of the present invention.

[0135] Figure 8 Show the influence of different groups on the number of OUTs in a specific experiment of the present invention.

[0136] Figure 9 Show the influence of different groups on the intestinal flora composition in a specific experiment of the present invention. Detailed implementation manners

[0137] Before further describing the specific implementation manners of the present invention, it should be understood that the protection scope of the present invention is not limited to the following specific implementation manners; it should also be understood that the terms used in the embodiments of the present invention are for describing specific implementation manners and not for limiting the protection scope of the present invention.

[0138] When an embodiment gives a numerical range, it should be understood that unless otherwise specified in the present invention, both endpoints of each numerical range and any value between the two endpoints can be selected.

[0139] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those skilled in the art of this technology.

[0140] Except for the specific methods, devices, and materials used in the embodiments, according to the knowledge of those skilled in the art of this technology and the description of the present invention, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention can also be used to implement the present invention.

[0141] Unless otherwise specified, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt the conventional techniques in the art of this technology.

[0142] In animal experiments, all reagent materials and test substances used are obtained by regular commercial purchase.

[0143] Efficacy experiment of 2'-fucosyllactose and osteopontin composition in improving intestinal inflammation symptoms and restoring key flora

[0144] In this study, fecal samples of healthy infants aged 3 - 6 months were collected, and an infant microbiota humanized rat model was constructed using fecal transplantation technology. The rats were divided into 5 groups: normal rat control group (NC group, gavaged with 1 mL of PBS daily), model group (LPS group, gavaged with 1 mL of PBS daily), 2’-FL group (gavaged with 1 mL of 2’-FL daily), OPN group (gavaged with 1 mL of OPN daily), and 2’-FL + OPN group (gavaged with 1 mL of a mixed solution of 2’-FL and OPN daily), with 12 rats in each group. After 14 days of gavage, the body weights of the rats in each group were measured. Except for the NC control group, the other 4 groups of rats were intervened with LPS (8 mg / kg body weight), and the body weights were measured again after continuous observation for 6 h. The gavage concentration of 2’-FL was 443 mg / kg body weight, the gavage concentration of OPN was 300 mg / kg body weight, and the dose of the mixed solution was the sum of the two. After the animal experiment, rat blood samples, as well as ileal terminal and colon tissues, were collected, and the MPO activity and DAO content in rat serum were detected using an ELISA kit (Solarbio, BC5715) according to the instructions.

[0145] The total RNA of the colon tissue was extracted after grinding and homogenizing in liquid nitrogen, and the extracted RNA was reverse transcribed into cDNA using a reverse transcription kit (Qiagen, 51340). The expression levels of MUC2, ZO-1, Claudin-1, and Claudin-2 in the colon tissue were measured using a PCR instrument.

[0146] The expression of CD4 and CD8 in the rat intestine was evaluated by immunofluorescence analysis, and the CD4 / CD8 ratio was calculated.

[0147] Finally, the total DNA was extracted using a genomic DNA extraction kit, and the samples were sequenced on an Illumina MiSeq high-throughput sequencer. The data of each sample were split from the downloaded data according to the Barcode sequence and PCR amplification primer sequence. After removing the Barcode and primer sequences, the FLASH software was used for sequence splicing. The results related to the intestinal flora composition of each group were obtained.

[0148] The group information is shown in Table 1:

[0149] Table 1

[0150] Group Details NC Group Normal rat group, gavaged with PBS, without LPS treatment LPS Group Model animal group, gavaged with PBS, with LPS treatment 2’-FL Monomer intervention group, gavaged with 2’-FL, with LPS treatment OPN Monomer intervention group, gavaged with OPN, with LPS treatment 2’FL + OPN 2’FL + OPN, gavaged with the composition, with LPS treatment

[0151] Experimental results:

[0152] 1. Changes in body weights of rats in each group before and after LPS treatment

[0153] All experimental rats were weighed before the start of LPS injection, and there were no significant differences among the groups. The results are as Figure 1As shown in the initial body weight part. Six hours after LPS injection, the body weights of the rats in the injection groups (LPS group, 2'-FL group, OPN group, and 2'-FL + OPN group) were significantly decreased compared with those of the non-injected rats (NC group), and the results are as Figure 2 shown.

[0154] 2. Myeloperoxidase (MPO) activity in the serum of each group

[0155] Myeloperoxidase (MPO) in the serum is a leukocyte enzyme mainly secreted by activated macrophages, neutrophils, and monocytes. When the body is under oxidative stress, such as infection or fever, the body can release a large amount of MPO, generate oxygen free radicals, promote the oxidation of low-density lipoprotein in the body, and promote the occurrence and development of inflammatory reactions.

[0156] The results are as Figure 3 shown. Compared with the NC group, after LPS treatment, the activity of MPO in the serum of rats in the LPS group increased significantly (p < 0.05), indicating that LPS treatment would cause an increase in the intestinal inflammation level. Compared with the LPS group, the serum MPO activities of the 2'-FL, OPN, and 2'-FL + OPN groups were significantly decreased. Compared with the other two groups, the 2'-FL + OPN group could better reduce the activity of MPO in the serum, and there was no significant difference from the NC group. The composition showed a certain synergistic effect, indicating that the 2'-FL + OPN group could reduce the damage of inflammation to the intestine by reducing the MPO activity.

[0157] 3. Diamine oxidase (DAO) level in the serum of each group

[0158] Diamine oxidase (DAO) is a structural enzyme specifically present in small intestinal mucosal epithelial cells. It is the key enzyme catalyzing the oxidation of histamine, and more than 90% exists in the small intestinal mucosa epithelium. The main role of DAO is to control the proliferation of intestinal mucosa, and its activity is closely related to the metabolism of intestinal mucosal epithelial cells. When the intestine is damaged or inflamed, the synthesis of DAO at the damaged site increases, and DAO then enters the blood. DAO exists stably in the serum, so it can reflect the situation of intestinal barrier damage and repair.

[0159] As Figure 4 shown, compared with the NC group, the serum DAO level of rats in the LPS group was significantly increased, indicating that the intestinal barrier of rats was severely damaged; compared with the LPS model group, the serum DAO level of the intervention group rats decreased significantly, indicating that their intestinal damage was protected to a certain extent. The 2'-FL + OPN composition was superior to the 2'-FL and OPN monomers in reducing the increase in DAO caused by LPS treatment, and there was no significant difference from the NC group, showing a certain synergistic effect.

[0160] 4. Intestinal goblet cell level

[0161] The intestinal epithelium is mainly composed of four types of cells: absorptive cells, goblet cells, Paneth cells, and endocrine cells. These cells are constantly renewed to ensure the integrity of the intestinal epithelium. Studies have shown that changes in the differentiation and secretory functions of goblet cells can lead to changes in the composition of the mucus layer, playing an important role in the occurrence and development of intestinal diseases.

[0162] The results were as Figure 5 shown. In the LPS group, there were epithelial cell shedding, inflammatory cell infiltration, and a decrease in goblet cells in the intestine. In the intervention groups, namely the 2’-FL group, OPN group, and 2’-FL + OPN group, the intestinal pathological conditions and the number of goblet cells were significantly improved. The number of goblet cells in the 2’-FL + OPN group was higher than that in the LPS group and the single-agent groups of 2‘-FL and OPN, indicating that 2'-FL and OPN have a certain effect on preventing tissue damage caused by LPS, and the combined effect of 2'-FL and OPN is better than the individual effects of 2'-FL and OPN.

[0163] 5. Gene expression levels of ileal mucin and tight junction proteins

[0164] Mucin is mainly composed of protein molecules, glycosyl compounds, amino acid residue modifiers, and metal ions, etc., and is one of the main components of the intestinal mucosal barrier. Members of the intestinal mucin family, such as mucin 1 (MUC1), mucin 2 (MUC2), mucin 5B (MUC5B), and mucin 13 (MUC13), are expressed in the intestine and play different functions. MUC2 consists of 5,100 amino acids and provides a protective barrier between the intestinal epithelial surface and the intestinal lumen. In addition to the mucosal barrier, tight junctions are composed of different occludin, claudin, and zonula occludens (ZO) proteins. These three types of proteins and the actin cytoskeleton connect adjacent cells to form the epithelial barrier.

[0165] The mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1 reflect the function of the intestinal barrier. The results were as Figure 6A - Figure 6DAs shown, compared with the NC group, the mRNA expression level in the LPS group was significantly decreased (P<0.05); the 2’-FL, OPN, and 2’-FL+OPN groups significantly changed this result and upregulated the mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1. In particular, in the 2'-FL+OPN group, the mRNA expression levels of MUC2, Claudin-1, Claudin-2, and ZO-1 were all significantly increased, showing the most obvious effect among all the intervention groups and even having no significant difference from the NC group (Claudin-1), indicating a certain synergistic effect.

[0166] 6. Expression of immune cells in each group

[0167] See the expression of immune cells in each group Figure 7A - Figure 7C . Compared with the NC group, the expression of CD4+ in the intestines of rats in the LPS group was significantly decreased, and the expression of CD4+ T cells in rats in the 2‘-FL, OPN, and 2’-FL+OPN groups was significantly increased. Compared with the NC group, the expression of CD8+ T cells in the LPS group was significantly increased, and the expression of CD8+ T cells in rats in the 2‘-FL, OPN, and 2’-FL+OPN groups was significantly decreased. The CD4+ / CD8+ T results showed that compared with the NC control group, the ratio of CD4+ / CD8+ T cells in the LPS group was significantly decreased (P<0.05), indicating that the proportion of intestinal immune cells in rats was dysregulated and the immune function was impaired after LPS treatment. In the 2‘-FL, OPN, and 2’-FL+OPN groups, the CD4+ / CD8+ was significantly increased, especially in the 2'-FL+OPN group, where the ratio of CD4+ / CD8+ T cells was increased most significantly, showing a certain coordinating effect.

[0168] 7. Effect of the combination of 2’-FL and OPN on intestinal flora

[0169] In this experiment, the effect of the 2’-FL+OPN composition on the intestinal flora of infants was further studied.

[0170] As Figure 8As shown, the specific OTUs in the NC group were significantly more than those in the LPS group, indicating that LPS treatment led to a significant reduction in the species of rat intestinal microbiota. The number of OTUs in the 2'-FL+OPN group recovered, suggesting that the 2’-FL+OPN group could significantly improve the reduction in intestinal microbiota species caused by intestinal mucosal immune injury. The results of α-diversity are shown in Table 1. The results showed that compared with the NC group, the observed species index, chao1 index, shannon index, and simpson index in the LPS group were all significantly decreased. Compared with the LPS group, the four indexes in the 2'-FL+OPN group were all significantly increased and there was no significant difference from the NC group. The results indicate that 2'-FL+OPN can significantly increase the diversity and richness of the microbial community.

[0171] The results of α-diversity are shown in Table 2. The results showed that compared with the NC group, the observed species index, chao1 index, shannon index, and simpson index in the LPS group were all significantly decreased. Compared with the LPS group, the four indexes in the 2'-FL+OPN group were all significantly increased. The results indicate that 2'-FL+OPN can significantly increase the diversity and richness of the microbial community.

[0172] Table 2. α-Diversity Analysis of Each Group

[0173] NC LPS 2'-FL + OPN chao1 618.98±48.23 472.70±15.60 621.86±10.93 observed_species 500.70±29.87 381.90±9.75 529.40±4.87 shannon 5.39±0.08 4.43±0.19 5.43±0.04 simpson 0.93±0.01 0.88±0.01 0.94±0.01

[0174] The 16s sequencing method was used to analyze the flora composition of intestinal microbiota. See the results of flora composition analysis in Figure 9The results showed that, compared with the NC control group, the abundances of Lactobacillus and Muribaculaceae in the LPS group decreased significantly by 9.09% and 8.11% respectively, while the abundances of Escherichia-Shigella and Alloprevotella increased significantly by 7.15% and 11.14% respectively. In the 2'-FL + OPN group, the abundance of Lactobacillus increased significantly by 10.12%, the abundance of Muribaculaceae increased significantly by 3.87%, the abundance of Alloprevotella decreased significantly by 21.11%, and the abundance of Escherichia-Shigella decreased by 2.01%. Changes in other genera included Eubacterium_coprostanoligenes_group, Romboutsia, Lachnoclostridium, Streptococcus, etc., but the changes were less or not significant. These changes indicated that the 2'-FL + OPN group successfully improved the gut microbiota structure compared with the LPS model group, especially reducing the abundances of some potentially harmful genera such as Escherichia-Shigella and Alloprevotella, and increasing the abundances of some potentially beneficial genera such as Lactobacillus and Muribaculaceae. The changes in other genera included some minor adjustments, making the microbiota structure of the 2'-FL + OPN group closer to that of the NC control group.

[0175] Example 1

[0176] This example provides an infant formula. The total protein content in this infant formula is 10.5 g / 100 g, the mass content of whey protein in the protein is 60%, the 2'-fucosyllactose content is 0.9 g / 100 g, the osteopontin content is 0.03 g / 100 g, the fat content is 27.0 g / 100 g, the dietary fiber content is 3.0 g / 100 g; and the carbohydrate content is 54.6 g / 100 g.

[0177] The raw material composition of this example includes:

[0178] 1250 kg of milk, 150 kg of lactose, 300 kg of demineralized whey powder, 60 kg of sunflower oil, 30 kg of corn oil, 20 kg of soybean oil, 100 kg of OPO structured lipid, 12 kg of α-lactalbumin powder, 10 kg of casein powder, 20 kg of fructooligosaccharide powder, 45 kg of galactooligosaccharide syrup, 12 kg of 2'-fucosyllactose, 2 kg of soy lecithin, 18.5 kg of compound nutrients, 12 kg of DHA, 14 kg of ARA, 0.6 kg of nucleotides, 0.3 kg of Bifidobacterium.

[0179] The preparation process is as follows:

[0180] 1) Coarse filtration of milk: After the milk passes through coarse filtration and degassing in the balance tank, it is preheated by a plate heat exchanger and then the impurities are separated by a separator.

[0181] 2) Homogenization and sterilization of milk: Part of the milk after removing impurities enters the homogenizer for homogenization, and the other part is not homogenized. The homogenized milk and the non-homogenized milk are mixed and then enter the sterilization system for sterilization. After sterilization, it enters the mixing tank.

[0182] 3) Addition of powders: The lactose and casein powder raw materials are premixed at an optimal ratio of 5:1, and the batching temperature is maintained at 35 - 55°C. High-shear technology is adopted with a shear speed higher than 1590 r / min. Other various powder raw materials are metered according to the formula and uniformly added to the powder mixing tank for storage through the pneumatic conveying system.

[0183] 4) Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the mixing tank through the vacuum system.

[0184] 5) Melting and oil blending: The oils specified in the formula are put into the oil melting room according to the formula requirements. The temperature in the oil melting room should be maintained at 50 - 90°C. After the oil is melted, it is pumped into the mixed oil storage tank according to the formula ratio requirements through an oil pump and a flow meter.

[0185] 6) Storage of mixed oil: The mixed oil is stored in the oil storage tank with heat preservation, the temperature is 40 - 50°C, and the storage time is less than 12 hours to prevent fat oxidation.

[0186] 7) Weighing: The mixed oil is pumped into the mixing tank through an oil pump according to the formula requirements.

[0187] 8) Dissolution and addition of compound nutritional fortifiers: Compound nutritional fortifier one, compound nutritional fortifier two, compound nutritional fortifier three, compound magnesium chloride nutritional package, compound potassium chloride nutritional package, and choline chloride are added respectively. After being dissolved with 100 - 200 kg of pure water respectively, they are pumped into the mixing tank. After each addition, the addition tank and pipeline are rinsed with 100 kg of pure water.

[0188] 9) Addition of minor ingredients: Galactooligosaccharide syrup is added in the minor ingredient hopper and pumped into the mixing tank.

[0189] 10) Filtration: Mix all raw materials in the mixing tank. The mixed liquid is filtered through a filter screen to remove physical impurities that may be introduced into the raw materials.

[0190] 11) Homogenization: The mixed liquid is homogenized by a homogenizer. The primary pressure is 105 ± 5 bar, and the secondary pressure is 32 ± 3 bar. Mechanically process the fat globules to disperse them into uniform fat globules.

[0191] 12) Cooling and storage: The homogenized liquid enters a plate heat exchanger for cooling. Cool it to below 20 °C and temporarily store it in a pre-storage tank. Enter the next process within 6 hours, and the agitator is turned on according to the set requirements.

[0192] 13) Concentration and sterilization: Use double-effect concentration during production. The sterilization temperature is ≥ 83 °C, and the sterilization time is 25 seconds; the discharge concentration is 48% - 52% dry matter.

[0193] 14) Storage of concentrated milk, preheating and filtration, spray drying: The concentrated milk is temporarily stored in a concentrated milk balance tank; preheat it to 60 - 70 °C through a scraper preheater. After preheating, the material is filtered through a filter with a 1 mm pore diameter and then pumped into a drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required; among them, the inlet air temperature is 165 - 180 °C, the exhaust air temperature is 75 - 90 °C, the pressure of the high-pressure pump is 160 - 210 bar, and the tower negative pressure is -4 mbar to -2 mbar.

[0194] 15) Fluidized bed drying and cooling: The milk powder coming out of the drying tower is further dried twice in the fluidized bed (primary) and then cooled to 25 - 30 °C in the fluidized bed (secondary); at the same time, mix phospholipids with a carrier and heat it to 60 - 65 °C. Under the action of compressed air, make the phospholipids evenly disperse on the surface of the milk powder to increase the particle size and instant solubility of the powder particles by agglomeration.

[0195] 16) Packaging: Weigh, seal, and package DHA, ARA, lactoferrin, nucleotides, and Bifidobacterium according to the formula requirements.

[0196] 17) Dry mixing: Mix the weighed DHA, ARA, lactoferrin, nucleotides, Bifidobacterium with the milk powder evenly in a dry mixer.

[0197] 18) Sieving the powder: Pass the milk powder through a vibrating sieve to make the particle size of the milk powder uniform, and dispose of the powder residue.

[0198] 19) Powder discharging: Use a disinfected powder collecting box to collect the powder and transport it from the powder discharging room to the powder feeding room.

[0199] 20) Powder feeding: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0200] 21) Packaging: Nitrogen-filled packaging using automatic packaging machines of different specifications; the oxygen content during nitrogen filling is less than 1 - 5%.

[0201] 22) Boxing: Put the packaged small bags into cartons and add powder spoons at the same time, and seal with a carton sealer.

[0202] 23) Final product inspection: Sample and inspect the products after packaging according to the inspection plan.

[0203] 24) Warehousing and storage: Qualified products after inspection are warehoused and stored, and it is required to store at room temperature with humidity ≤ 65%.

[0204] After testing, the various indicators of this final product meet the requirements of the infant formula standard.

[0205] The above description of the embodiments is for the convenience of those of ordinary skill in the art to understand and use the invention. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative efforts. Therefore, the present invention is not limited to the above embodiments, and the improvements and modifications made by those skilled in the art without departing from the scope of the present invention according to the disclosure of the present invention should be within the protection scope of the present invention.

Claims

1. An infant formula milk powder, comprising 2'-fucosyllactose and osteopontin, wherein the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.017-1.3); and each 100g of the infant formula milk powder comprises 8-24g of protein, 14-31g of fat, 0.83-7.6g of dietary fiber, and 50-61g of carbohydrates.

2. The infant formula milk powder according to claim 1, wherein The mass content of whey protein in protein is 20%-90%.

3. The infant milk powder according to claim 1 or 2, wherein: The mass ratio of 2'-fucosyllactose to osteopontin was 1:(0.1-1.3); Preferably, the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.2-1.3); Preferably, the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.25-1.3).

4. The infant formula milk powder according to any one of claims 1 to 3, wherein the amount of 2'-fucosyllactose contained is 0.5-1.8 g / 100 g.

5. The infant formula milk powder according to any one of claims 1 to 3, wherein the amount of 2'-fucosyllactose contained is 0.6-0.7 g / 100g, 0.8-0.9 g / 100g, 1.0-1.1 g / 100g, 1.2-1.3 g / 100g, 1.4-1.5 g / 100g or 1.6-1.7 g / 100g.

6. The infant formula milk powder according to claim 1, wherein the raw materials thereof comprise:

7. A method for preparing the infant formula milk powder according to any one of claims 1 to 6, the method comprising: The raw materials providing 2'-fucosyllactose and osteopontin are mixed with other raw materials in the formula by adopting a wet method, a dry method or a dry-wet composite production process. The mixed materials are homogenized after filtering and removing impurities, and are further used to prepare the infant formula milk powder.

8. The preparation method according to claim 7, comprising: The milk, powder raw materials and melted oil raw materials that have been coarsely filtered, homogenized and sterilized are mixed, galacto-oligosaccharide syrup is added to a small hopper, and compound nutrients are added to a nutrient tank, and mixed to obtain a mixed liquid; The mixed liquid is filtered, homogenized, cooled, concentrated and sterilized, spray-dried, and fluidized bed dried and cooled to obtain dry milk powder, which is mixed with selectively added DHA, ARA, lactoferrin, nucleotides, and bifidobacteria, and sieved to obtain the infant milk powder; Preferably, the primary pressure of the homogenization treatment of the mixed liquid is 105±5 bar, and the secondary pressure is 32±3 bar; Preferably, the concentration and sterilization adopts double-effect concentration; more preferably, the sterilization temperature is ≥83°C and the sterilization time is 25 seconds; further preferably, the discharge concentration is 48%-52% dry matter; Preferably, the inlet air temperature of the spray drying is 165-180°C, the exhaust air temperature is 75-90°C, the high-pressure pump pressure is 160-210 bar, and the tower negative pressure is -4 mbar to -2 mbar; Preferably, the fluidized bed drying and cooling includes two drying and cooling steps, and the temperature of the milk powder after the second drying and cooling step is 25-30°C; at the same time, the phospholipids and the carrier are mixed and heated to 60-65°C, and evenly dispersed on the surface of the milk powder under the action of compressed air.

9. Use of the infant formula milk powder according to any one of claims 1 to 6 in the preparation of a product for improving symptoms of intestinal inflammation and restoring key flora.

10. The use according to claim 9, wherein: Improving intestinal inflammation symptoms and restoring key flora include one or more of the following: Improve weight loss caused by intestinal inflammatory response; Improve intestinal damage caused by inflammatory response; Reduce the increase in serum myeloperoxidase (MPO) activity caused by intestinal inflammatory response; Reduce the increase in serum diamine oxidase (DAO) levels caused by intestinal inflammatory response; Improve the level of intestinal goblet cells (improve the decrease in the level of ring cells caused by intestinal inflammatory response); Improve intestinal barrier function; strengthening the intestinal physical and / or mucus barrier; Increase the expression level of intestinal mucin (improve the decrease of mucin level caused by intestinal inflammatory response); Increase the expression level of intestinal tight junction proteins (improve the decrease in tight junction protein levels caused by intestinal inflammatory response); Maintain intestinal cell immune homeostasis; Improve intestinal immune cell disorders caused by inflammatory response; Increase intestinal CD4+T cell expression; Reduce intestinal CD8+T cell expression; Improve the ratio of intestinal CD4+ / CD8+T cells; Improving the diversity and / or richness of the intestinal microbiome; Restoring the disturbance or reduced diversity of the intestinal cornerstone flora caused by inflammation or antibiotics; Improve the reduction of intestinal microbial species caused by intestinal mucosal immune damage; Increase the abundance of the enteric bacterial genera Muribaculaceae and / or Lactobacillus; Reduces intestinal Escherichia-Shigella and / or Pseudomonas (Alloprevotella) abundance.

Images